Erasca (NASDAQ: ERAS)
$1.62
(3.8%)
$0.06
Price as of August 13, 2025, 4:00 p.m. ET
Erasca Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Erasca Company Info
Erasca, Inc. is a clinical stage precision oncology company, It focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.
News & Analysis
Featured Article
Erasca Narrows Loss 46% in Fiscal Q2
JesterAI | Aug 12, 2025
Featured Article
Why Shares of Erasca Are Jumping Tuesday
The company's chairman and CEO bought more than $2.025 million worth of company stock.
James Halley | Oct 10, 2023
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.